ALPHA.SF ULTRA ERK 1/2 PT202/Y204-Revvity
Order
Cat.NO Name Size
ALSU-PERK-A50K ALPHA.SF ULTRA ERK 1/2 PT202/Y204 50K

 

  • Product overview
  • Brand introduction
  • Q&A
  • Data download

Formats:

  • The HV (high volume) kit contains reagents to run 100 wells in 96-well format, using a 60 µL reaction volume.
  • The 500-point kit contains enough reagents to run 500 wells in 384-well format, using a 20 µL reaction volume.
  • The 10,000-point kit contains enough reagents to run 10,000 wells in 384-well format, using a 20 µL reaction volume.
  • The 50,000-point kit contains enough reagents to run 50,000 wells in 384-well format, using a 20 µL reaction volume.

 

In the AlphaLISA™ SureFire® Ultra™ assay, Donor beads are coated with streptavidin to capture one of the antibodies, which is biotinylated. Acceptor beads are coated with a proprietary CaptSure™ agent that immobilizes the other antibody, labeled with a CaptSure™ tag. In the presence of phosphorylated protein, the two antibodies bring the Donor and Acceptor beads close together, generating signal. The amount of light emission is directly proportional to the amount of phosphoprotein present in the sample.

 

AlphaLISA™ SureFire® Ultra™ kits are compatible with:

  • Cell and tissue lysates
  • Antibody modulators
  • Biotherapeutic antibodies

 

Alpha SureFire® kits can be used for:

  • Cellular kinase assays
  • Receptor activation studies
  • Screening

Specifications

 

 

Revvity, we regard "impossibility" as inspiration and "inability" as the driving force. Revvity offers health science solutions, cutting - edge technologies and professional services, with its business covering the entire end - to - end process of scientific research exploration, development, diagnosis, and treatment. Relying on years of in - depth cultivation in fields such as translational multi - omics technology, biomarker identification, imaging, disease prediction, screening, detection and diagnosis, and informatics, Revvity is using the power of technology to break through the boundaries of human potential.

 

In 2023, Revvity's turnover exceeded $2.7 billion. It has more than 11,000 employees worldwide and provides diverse services for customers such as pharmaceutical and biotechnology enterprises, diagnostic laboratories, scientific research institutions and government agencies. The company is a member of the S&P 500 Index, and its customers are spread across more than 190 countries and regions around the world.

×